Portal vein thrombosis diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) |
Farima Kahe (talk | contribs) |
||
| Line 8: | Line 8: | ||
=== Gold standard/Study of choice: === | === Gold standard/Study of choice: === | ||
* Ultrasonography is the gold standard test for the diagnosis of portal vein thrombosis. | * Ultrasonography is the gold standard test for the diagnosis of portal vein thrombosis.<ref name="pmid25941431">{{cite journal |vauthors=Chawla YK, Bodh V |title=Portal vein thrombosis |journal=J Clin Exp Hepatol |volume=5 |issue=1 |pages=22–40 |year=2015 |pmid=25941431 |pmc=4415192 |doi=10.1016/j.jceh.2014.12.008 |url=}}</ref> | ||
* Among patients who present with clinical signs of absence or reduced flow in portal vein, the contrast enhanced ultrasound (CDUS) is the most specific test for the diagnosis. | * Among patients who present with clinical signs of absence or reduced flow in portal vein, the contrast enhanced ultrasound (CDUS) is the most specific test for the diagnosis. | ||
Revision as of 20:57, 18 December 2017
|
Portal vein thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Portal vein thrombosis diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Portal vein thrombosis diagnostic study of choice |
|
Portal vein thrombosis diagnostic study of choice in the news |
|
Risk calculators and risk factors for Portal vein thrombosis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Diagnostic Study of Choice
Gold standard/Study of choice:
- Ultrasonography is the gold standard test for the diagnosis of portal vein thrombosis.[1]
- Among patients who present with clinical signs of absence or reduced flow in portal vein, the contrast enhanced ultrasound (CDUS) is the most specific test for the diagnosis.
Diagnostic results
The following result of ultrasonography is confirmatory of portal vein thrombosis:
- Portal cavernoma (multiple tortuous small vessels replacing the portal vein)
- Absence or reduced flow in portal vein
Diagnostic Criteria
- Benign portal vein thrombosis may be diagnosed at any time if one or more of the following criteria are met:[2][3]
- Lack of vascularization of the thrombus on contrast-enhanced ultrasound(CEUS)
- Absence of mass-forming features of the thrombus on CT or MRI
- Absence of disruption of the walls of veins on CT or MRI
- Absence of evidence of disruption of vessel walls
- No features of malignancy in a biopsy sample of the thrombus
- Stability or regression of the thrombus during follow-up
- Malignant portal vein thrombosis may be diagnosed at any time if one or more of the following criteria are met:[4]
- Expansion of the involved vessel (vessel diameter > 1.8 cm) for the main portal vein
- Tumor size >5 cm and distance <2 cm
References
- ↑ Chawla YK, Bodh V (2015). "Portal vein thrombosis". J Clin Exp Hepatol. 5 (1): 22–40. doi:10.1016/j.jceh.2014.12.008. PMC 4415192. PMID 25941431.
- ↑ Piscaglia, Fabio; Gianstefani, Alice; Ravaioli, Matteo; Golfieri, Rita; Cappelli, Alberta; Giampalma, Emanuela; Sagrini, Elisabetta; Imbriaco, Grazia; Pinna, Antonio Daniele; Bolondi, Luigi (2010). "Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinom for liver transplantation". Liver Transplantation: NA–NA. doi:10.1002/lt.22044. ISSN 1527-6465.
- ↑ Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, Golfieri R, D'Errico Grigioni A, Panzini I, Morelli C, Bernardi M, Bolondi L, Pinna AD (2008). "Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria". Am. J. Transplant. 8 (12): 2547–57. doi:10.1111/j.1600-6143.2008.02409.x. PMID 19032223.
- ↑ Osman, Nasr Mohamed Mohamed; Samy, Laila Adel Mohamed (2016). "Benign and malignant portal venous thrombosis: Multi-modality imaging evaluation". The Egyptian Journal of Radiology and Nuclear Medicine. 47 (2): 387–397. doi:10.1016/j.ejrnm.2016.02.010. ISSN 0378-603X.